公开(公告)号：US20220111148A1

公开(公告)日：2022-04-14

申请号：US17556761

申请日：2021-12-20

Applicant: DexCom, Inc.

Inventor： James H. Brauker ,  Mark A. Tapsak ,  Sean T. Saint ,  Apurv Ullas Kamath ,  Paul V. Neale ,  Peter C. Simpson ,  Michael Robert Mensinger ,  Dubravka Markovic

IPC: A61M5/315 ,  A61B5/1486 ,  A61M15/00 ,  A61M11/00 ,  A61B5/00 ,  A61B5/145 ,  A61M5/172 ,  G16H40/63 ,  G16H10/40 ,  G16H20/17

Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

公开(公告)号：US10791928B2

公开(公告)日：2020-10-06

申请号：US16796830

申请日：2020-02-20

Applicant: DexCom, Inc.

Inventor： Peter C. Simpson ,  Robert J. Boock ,  Mark C. Brister ,  Monica A. Rixman ,  Kum Ming Woo ,  Lisa Nguyen ,  Seth R. Brunner ,  Arthur Chee ,  Melissa A. Nicholas ,  Matthew D. Wightlin ,  Jack Pryor ,  Dubravka Markovic

IPC: A61B5/145 ,  A61B5/00 ,  A61B5/1486 ,  A61B5/1473

Abstract: Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

公开(公告)号：US20130131478A1

公开(公告)日：2013-05-23

申请号：US13732848

申请日：2013-01-02

Applicant: DEXCOM, INC.

Inventor： Peter C. Simpson ,  Robert J. Boock ,  James R. Petisce ,  Mark C. Brister ,  Monica A. Rixman ,  Kum Ming Woo ,  Lisa Nguyen ,  Seth R. Brunner ,  Arthur Chee ,  Melissa A. Nicholas ,  Matthew D. Wightlin ,  Jack Pryor ,  Dubravka Markovic

IPC: A61B5/1486 ,  A61B5/145 ,  A61B5/00 ,  A61B5/1473

CPC classification number: A61B5/14735 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1473 ,  A61B5/1486 ,  A61B5/14865 ,  A61B5/6848 ,  A61B5/7203

Abstract: Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

Abstract translation: 提供涉及具有基本上不受非恒定噪声影响的信噪比的传感器的系统和方法用于主机中的连续分析物测量。 在一些实施例中，连续分析物测量系统被配置为完全，经皮，血管内或体外植入。

公开(公告)号：US20200375515A1

公开(公告)日：2020-12-03

申请号：US16998841

申请日：2020-08-20

Applicant: DexCom, Inc.

Inventor： Mark Shults ,  James H. Brauker ,  Victoria Carr-Brendel ,  Mark Tapsak ,  Dubravka Markovic

IPC: A61B5/1486 ,  A61B5/145 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16

Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

公开(公告)号：US20140128703A1

公开(公告)日：2014-05-08

申请号：US14145404

申请日：2013-12-31

Applicant: DexCom, Inc.

Inventor： Peter C. Simpson ,  Robert J. Boock ,  Mark C. Brister ,  Monica A. Rixman ,  Kum Ming Woo ,  Lisa Nguyen ,  Seth R. Brunner ,  Arthur Chee ,  Melissa A. Nicholas ,  Matthew D. Wightlin ,  Jack Pryor ,  Dubravka Markovic

IPC: A61B5/145 ,  A61B5/1486

CPC classification number: A61B5/00 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1473 ,  A61B5/14735 ,  A61B5/1486 ,  A61B5/14865 ,  A61B5/6848 ,  A61B5/7203

Abstract: Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

公开(公告)号：US20220203038A1

公开(公告)日：2022-06-30

申请号：US17696198

申请日：2022-03-16

Applicant: DexCom, Inc.

Inventor： James H. Brauker ,  Mark A. Tapsak ,  Sean T. Saint ,  Apurv Ullas Kamath ,  Paul V. Neale ,  Peter C. Simpson ,  Michael Robert Mensinger ,  Dubravka Markovic

IPC: A61M5/315 ,  A61M11/00 ,  A61M5/172 ,  G16H20/17 ,  A61M15/00 ,  A61B5/145 ,  A61B5/00 ,  A61B5/1486 ,  G16H10/40 ,  G16H40/63

Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

公开(公告)号：US11246990B2

公开(公告)日：2022-02-15

申请号：US15906946

申请日：2018-02-27

Applicant: DexCom, Inc.

Inventor： James H. Brauker ,  Mark A. Tapsak ,  Sean T. Saint ,  Apurv Ullas Kamath ,  Paul V. Neale ,  Peter C. Simpson ,  Michael Robert Mensinger ,  Dubravka Markovic

IPC: A61M31/00 ,  A61M1/00 ,  A61M5/315 ,  A61B5/1486 ,  A61M15/00 ,  A61M11/00 ,  A61B5/00 ,  A61B5/145 ,  A61M5/172 ,  G16H40/63 ,  G16H10/40 ,  G16H20/17

Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

公开(公告)号：US20200037874A1

公开(公告)日：2020-02-06

申请号：US16599019

申请日：2019-10-10

Applicant: DexCom, Inc.

Inventor： Peter C. Simpson ,  Robert J. Boock ,  Mark C. Brister ,  Monica A. Rixman ,  Kum Ming Woo ,  Lisa Nguyen ,  Seth R. Brunner ,  Arthur Chee ,  Melissa A. Nicholas ,  Matthew D. Wightlin ,  Jack Pryor ,  Dubravka Markovic

IPC: A61B5/00 ,  A61B5/1486 ,  A61B5/1473 ,  A61B5/145

Abstract: Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

公开(公告)号：US09937293B2

公开(公告)日：2018-04-10

申请号：US14830568

申请日：2015-08-19

Applicant: DexCom, Inc.

Inventor： James H. Brauker ,  Mark A. Tapsak ,  Sean T. Saint ,  Apurv Ullas Kamath ,  Paul V. Neale ,  Peter C. Simpson ,  Michael Robert Mensinger ,  Dubravka Markovic

IPC: A61M31/00 ,  A61M1/00 ,  A61M5/315 ,  A61B5/1486 ,  A61M15/00 ,  A61M11/00 ,  A61B5/00 ,  A61B5/145 ,  G06F19/00 ,  A61M5/172

CPC classification number: A61M5/31525 ,  A61B5/0002 ,  A61B5/14532 ,  A61B5/1486 ,  A61B5/14865 ,  A61B5/4839 ,  A61B2560/0443 ,  A61M5/1723 ,  A61M11/00 ,  A61M15/0001 ,  A61M2005/1726 ,  A61M2205/18 ,  A61M2205/3303 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  G06F19/00 ,  G06F19/3468 ,  G16H20/17 ,  G16H40/63

Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

公开(公告)号：US12115357B2

公开(公告)日：2024-10-15

申请号：US17696198

申请日：2022-03-16

Applicant: DexCom, Inc.

Inventor： James H. Brauker ,  Mark A. Tapsak ,  Sean T. Saint ,  Apurv Ullas Kamath ,  Paul V. Neale ,  Peter C. Simpson ,  Michael Robert Mensinger ,  Dubravka Markovic

IPC: A61M5/315 ,  A61B5/00 ,  A61B5/145 ,  A61B5/1486 ,  A61M5/172 ,  A61M11/00 ,  A61M15/00 ,  G16H10/40 ,  G16H20/17 ,  G16H40/63

CPC classification number: A61M5/31525 ,  A61B5/0002 ,  A61B5/14532 ,  A61B5/14865 ,  A61B5/4839 ,  A61M5/1723 ,  A61M11/00 ,  A61M15/0001 ,  G16H10/40 ,  G16H20/17 ,  G16H40/63 ,  A61B5/1486 ,  A61B2560/0443 ,  A61M2005/1726 ,  A61M2205/18 ,  A61M2205/3303 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.